**Supplemental Tables 2.** Patient overall assessment (ocular and visual discomfort) in the per Protocol Set.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | NSAID group (n=99) | *Intragroupp value\** | Steroid group (n=99) | *Intragroupp value\** | *Intergroup p value\** |
| Ocular discomfort (pain, foreign body sensation)  |
| Day 1 | 0.83±0.95(0.00, 4.00) |  | 0.98±1.01(0.00, 4.00) |  | 0.1358 |
| Week 1 | 0.64±0.85(0.00, 4.00) |  | 1.23±1.38(0.00, 6.00) |  | <0.0001 |
| Week 4 | 0.65±0.86(0.00, 4.00) |  | 0.96±1.16(0.00, 5.00) |  | 0.0093 |
| Week 8 | 0.99±1.21(0.00, 6.00) |  | 0.97±1.27(0.00, 6.00) |  | 0.8997 |
| Δ Week 1 to Day 1 | -0.19±1.17 | 0.0656 | 0.25±1.39 | 0.1067 | 0.0010 |
| Δ Week 4 to Day 1 | -0.17±1.07 | 0.1035 | -0.02±1.53 | 0.7750 | 0.3741 |
| Δ Week 8 to Day 1 | 0.15±1.41 | 0.4482 | -0.03±1.64 | 0.5350 | 0.1712 |
| Visual discomfort (glare, disturbance, blur) |
| Day 1 | 0.63±0.92(0.00, 4.00) |  | 0.65±0.96(0.00, 4.00) |  | 0.8847 |
| Week 1 | 0.60±1.00(0.00, 6.00) |  | 0.85±1.23(0.00, 7.00) |  | 0.0040 |
| Week 4 | 0.80±1.09(0.00, 5.00) |  | 0.86±1.11(0.00, 5.00) |  | 0.5490 |
| Week 8 | 0.91±1.21(0.00, 5.00) |  | 0.97±1.34(0.00, 6.00) |  | 0.3047 |
| Δ Week 1 to Day 1 | -0.03±0.90 | 0.7645 | 0.20±1.02 | 0.0656 | 0.0131 |
| Δ Week 4 to Day 1 | 0.16±1.12 | 0.1988 | 0.20±1.08 | 0.0632 | 0.6530 |
| Δ Week 8 to Day 1 | 0.26±1.27 | 0.0497 | 0.30±1.43 | 0.0572 | 0.5786 |

Mean±Standard deviation (Minimum, Maximum)

\* Wilcoxon’s signed rank test